Investors

Overview

Tourmaline is a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases.

Change
Volume
March 23, 2026 2:45 PM EDT

Minimum 15 minutes delayed. Source: LSEG

background image

News

September 9, 2025
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
Read More
August 31, 2025
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
Read More
August 13, 2025
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Read More

Events

May 20, 2025 8:30 AM EDT
Phase 2 TRANQUILITY Trial Topline Data
Read More
March 11, 2025 4:20 PM EDT
Leerink's Global Healthcare Conference 2025, Miami
Read More
February 5, 2025 1:30 PM EST
Guggenheim SMID Cap Biotech Conference, New York
Read More

Presentation

August 18, 2025
Tourmaline Corporate Overview - August 2025
Read More

Investor Information